News from Tuesday, December 24, 2024
Articles
Expanding Data Access for Researchers
(12/23, Todd Kohlhepp, Mathematica) comments “...Regional collaborations also offer researchers access to large amounts of data. For example, [Mathematica Data Innovations Director Ngan MacDonald] pointed to the Chicago Area Patient-Centered Outcomes Research Network (CAPriCORN), which enables researchers to securely access electronic health record data in the greater Chicago area that wouldn't otherwise be possible-while also protecting patient privacy.” Full
How the Contact Center Can Be a Driver of VBC Success
(12/23, Patty Hayward, Managed Healthcare Executive) comments “...Provider and payvider — an integrated healthcare entity that combines the role of a healthcare payer and a provider — organizations seeking the most value from their VBC contracts must fully leverage patient and member data in both clinical settings and in the contact center. This integrated approach will result in better patient and population health outcomes and lower overall costs of care while driving additional revenue — all of which help make risk-based contracts work for providers and payviders.” Full
CMS Explains What Went into its First Round of Drug Price Negotiations
(12/23, Zachary Brennan and Nicole DeFeudis, Endpoints News) reports “...CMS said it wants earlier and more flexible communication with drugmakers during this next round of negotiations. Multiple drugmakers participating in the first round of negotiations have complained that the process was not transparent or objective, likening the process to price-setting. A Novartis spokesperson told Endpoints News on Monday that the process ‘does not reflect the true value of a medicine.’” Full
Lilly Obesity Drug Mounjaro to Be Offered in Britain's NHS after Watchdog Nod
(12/24, Maggie Fick, Reuters) reports “...NICE, the National Institute for Health and Care Excellence, is recommending Mounjaro, alongside diet and exercise changes, for people with at least one weight-related condition, such as heart disease or type-2 diabetes, and a body mass index (BMI) - a measure of body fat based on height and weight - of more than 35.” Full
Journals
Cost-Effectiveness of Caplacizumab in Immune Thrombotic Thrombocytopenic Purpura in the United States
Sean D. Sullivan, PhD, Shruti Chaturvedi, MD, Preety Gautam, MA, and Alix Arnaud, MSc
December 23, 2024, Journal of Managed Care & Specialty Pharmacy